病例报道：吡咯替尼和替加氟联合放疗对HER2扩增的多发转移直肠癌多线治疗后取得显着疗效。
Case report: Pyrotinib and tegafur combined with radiotherapy achieved notable response in HER2-amplified rectal cancer with multiple metastases after multiline treatments.
发表日期：2024
作者：
Peng Huang, Feng Wen, Xin Wang
来源：
Frontiers in Pharmacology
摘要：
转移性结直肠癌（mCRC）的特点是分子水平上显着的表型异质性，预后不良。化疗通常被用作主要治疗选择。然而，化疗的优势受到限制，这凸显了旨在改善患者预后的新型治疗方案的迫切必要性。人表皮生长因子受体 2 (HER2) 已被认为是转移性结直肠癌 (mCRC) 有前景的治疗靶点。吡咯替尼是一种针对 HER2 的创新型不可逆双酪氨酸激酶抑制剂，可有效抑制多种人类癌症的进展。在这里，我们介绍了一名 39 岁女性的病例，她患有转移性直肠癌，显示 HER2 扩增。尽管对曲妥珠单抗和帕妥珠单抗等多种疗法产生耐药性，但该患者对吡咯替尼、替加氟联合放疗表现出显着的治疗反应。该病例为即使对其他抗 HER2 药物耐药的 HER2 扩增转移性结直肠癌患者使用吡咯替尼进行挽救治疗的可行性和潜在疗效提供了证据。版权所有 © 2024 Huang、Wen 和 Wang。
Metastatic colorectal cancer (mCRC) is characterized by significant phenotypic heterogeneity at the molecular level and presents a poor prognosis. Chemotherapy is commonly employed as the primary treatment option. Nevertheless, the advantages of chemotherapy are constrained, underscoring the critical necessity for novel treatment protocols aimed at enhancing patient outcomes. Human epidermal growth factor receptor 2 (HER2) has been recognized as a promising therapeutic target in mCRC. Pyrotinib, an innovative irreversible dual tyrosine kinase inhibitor targeting HER2, effectively inhibits cancer progression in various types of human cancers. Here, we present a case of a 39-year-old female with metastatic rectal cancer showing amplification of HER2. Despite resistance to multiple therapies, including trastuzumab and pertuzumab, the patient exhibited a remarkable therapeutic response to pyrotinib, tegafur combined with radiotherapy. This case provides evidence for the feasibility and potential efficacy of deploying pyrotinib in the salvage treatment of mCRC patients with HER2 amplification even though resistant to other anti-HER2 drugs.Copyright © 2024 Huang, Wen and Wang.